摘要
目的观察全身化疗联合腹腔化疗对晚期卵巢癌的疗效及毒副反应。方法24例卵巢癌，用紫杉醇135mg／m^2，卡铂400mg／m^2静滴，每4周重复1次，共化疗2个周期，顺铂60mg，地塞米松10mg腹腔化疗，每2周1次，进行2～3个周期，中位疾病进展时间（MTTP）9个月（5～12个月），无复发生存期5个月，观察每次化疗毒副反应及疗效。结果24例中CR12例、PR7例，RR79．2％，毒副反应为剂量限制性骨髓抑制、消化道反应。结论全身化疗联合腹腔化疗对晚期卵巢癌有较好疗效。
Objective To evaluate the results and toxicity of chemotherapy combined with intraperitoneal chemotherapy in advanced ovarian carcinoma. Methods 24 cases with advanced ovarian carcinoma were treated with paclitaxel 135 mg/m^2 and carboplatin 400 mg/m^2 intravenous chemotherapy, eisplatin 60 mg and dexamethasone 10 mg intraperitoneal chemotherapy. Results 24 cases were eligible for evaluation, the overall response rate was 79.2% （ 12 complete response and 7 partial response）, median TTP were 9 months （5-12 months） . The doselimited toxicity was mild and mainly expressed as arrest of bone marrow, nausea, vomiting. Conclusion A higher response rate is attainable in patients with advanced ovarian carcinoma by chemotherapy and intraperitoneal chemotherapy.
出处
《肿瘤基础与临床》
2008年第6期483-484,共2页
journal of basic and clinical oncology
关键词
卵巢癌
紫杉醇
卡铂
顺铂
化疗
ovarian carcinoma
paclitaxel
carboplatin
cisplatin
chemotherapy
